2025 is an exciting year for Europe from the access perspective: the EU HTA Regulation enters into force with first JCA submissions; NICE and HTA bodies from other parts of the world are evolving their collaboration; and the General Pharma Legislation aims to improve access across Europe. This track seeks to discuss these aspects, and some others further in the horizon, such as Net Zero impact of new technologies to the environment.

Who is This Track Designed For?

Value demonstration and patient access is relevant across different stakeholders. This track is designed for clinical, regulatory, patient, and value and market access experts who are interested in the link between technology innovators, regulatory, HTA and local decision-making, and how collaboration and engagement can improve patient access.

We invite abstracts containing multifunctional/multistakeholder perspectives (at a minimum Regulatory and Access perspectives) and gender balance is encouraged.